News | Proton Therapy | March 28, 2022

P-Cure in Israel developed a system intended for installations in existing radiation therapy rooms, targeting the largest radiotherapy market of equipment replacement

P-Cure Ltd., the provider of the most compact 360° gantry-less adaptive proton therapy system, announced today the opening of a clinical research and training site within its headquarters in Israel.

March 28, 2022 — P-Cure Ltd., the provider of the most compact 360° gantry-less adaptive proton therapy system, announced today the opening of a clinical research and training site within its headquarters in Israel. The site is conveniently located in a 20-minute drive from either Tel Aviv or Jerusalem and hosts the world’s most compact proton therapy system, which is installed within the footprint of a standard radiotherapy linac vault.

The site is established as a clinical platform of excellence to deliver and develop proton therapy protocols for patients as well as train existing and new customers. This training will enable fast technology adaptation by new treatment providers not familiar with proton therapy.

Located within the P-Cure Research and Development Center, the comprehensive site comprises a fully operational clinically designed proton treatment system, including compact accelerator, a 360° gantry-less treatment room, and access to all treatment and delivery planning – all within the space of existing linac vaults.

“P-Cure has developed a proton therapy system that shifts the paradigm in the ability of oncology centers around the world to be able to offer proton therapy to their patients,” says Dr. Sion Koren, Chairman of Medical Physics Association, Israel. “Instead of building a stand-alone facility, a cancer treatment center can expand its treatment options by installating a compact P-Cure Proton Therapy System in already existing linac vault.”

“We are excited to open our operational proton therapy site for clinical research and training, as well as for demonstrating the opportunity for oncology centers to expand their cancer fighting potential to include proton therapy. By utilizing the P-Cure system, this would be achieved without the expense of construction, the need for large and expensive equipment, and with the full patient and clinical benefits of treatment in a comfortable, seated position,” says Michael Marash, P-Cure CEO. “P-Cure is proud to become a member of the world-wide research community expanding the clinical benefits of proton therapy and demonstrating what is the most cost-effective system available to existing oncology centers.”

“P-Cure started by designing a patient-centric image guided adaptive positioning system, now expanding the offer by providing the most compact full proton therapy system that simulates, plans, positions and treats patients with enhanced patient comfort and clinical results, treating all treatment indications with adaptive, personalized proton therapy protocols,” Marash said.

Proton therapy has proven its cancer treatment patient protocols since the first hospital-based proton center started treating patients 32 years ago. Specifically, proton therapy is more precise than any other form of radiation. Unlike x-ray treatment, with proton therapy there is small amount of entrance radiation, but virtually none travels beyond the tumor. This benefit of proton therapy results in eliminating many of the harmful side effects of radiation therapy, as well as allowing physicians to safely deliver higher doses of radiation to tumors.

However, even with the clinical benefits of proton therapy, there are only 112 operational centers world-wide. Less than 2% of the patients that can benefit from proton therapy have access to this advanced form of treatment. The limiting factor has been the cost of equipment and construction. The typical total cost of a completed single room center can be more than $50 million. “With a P-Cure center, we eliminate the cost of construction and cutting half a cost of equipment. The compact P-Cure system installed inside existing radiation oncology departments removes the economic barrier to offering more patients the benefits of proton therapy,” says Marash.

“A possibility to install proton therapy within existing treatment centers expands for P-Cure a replacement market, making our system competitive and more advantageous to the over 1,000 radiation therapy modalities sold annually. We truly believe that this is a new era of radiation therapy, and a new opportunity for P-Cure to become market leader in providing the most targeted modality to treat cancer with radiation,” Marash adds.

For more information: www.p-cure.com


Related Content

News | FDA

March 1, 2024 — Varian, a Siemens Healthineers company, announced that it has received 510(k) clearance from the U.S ...

Time March 01, 2024
arrow
News | Breast Imaging

February 22, 2024 — The FAST-Forward randomized trial from the UK found that ultrahypofractionated whole breast ...

Time February 22, 2024
arrow
News | Radiation Oncology

February 22, 2024 — The National Institutes of Health has launched a clinical trials network to evaluate emerging ...

Time February 22, 2024
arrow
News | Radiation Oncology

February 14, 2024 — Accuray Incorporated announced that the team at Quebec’s Montérégie Integrated Cancer Center, part ...

Time February 14, 2024
arrow
News | Radiation Oncology

February 12, 2024 — Radformation, a global pioneer in radiation oncology software solutions, is pleased to announce its ...

Time February 12, 2024
arrow
News | Quality Assurance (QA)

February 12, 2024 — IBA, a world leader in particle accelerator technology and a world-leading provider of dosimetry and ...

Time February 12, 2024
arrow
News | Radiation Therapy

February 8, 2024 — RaySearch Laboratories AB announced that The Royal Marsden NHS Foundation Trust, a specialist cancer ...

Time February 08, 2024
arrow
Videos | RSNA

At RSNA23, Imaging Technology News (ITN) spoke with Bhvita Jani, principal analyst at Signify Research, about ...

Time February 07, 2024
arrow
News | Interventional Radiology

February 6, 2024 — RenovoRx, Inc., a clinical-stage biopharmaceutical company developing novel precision oncology ...

Time February 06, 2024
arrow
News | Treatment Planning

February 2, 2024 — RaySearch Laboratories announced that the number of radiotherapy centers that have chosen RayStation ...

Time February 02, 2024
arrow
Subscribe Now